Literature DB >> 17693890

Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique.

Cynthia R Pearson1, Mark A Micek, Jane M Simoni, Peter D Hoff, Eduardo Matediana, Diane P Martin, Stephen S Gloyd.   

Abstract

OBJECTIVE: To assess the efficacy of a peer-delivered intervention to promote short-term (6-month) and long-term (12-month) adherence to HAART in a Mozambican clinic population.
DESIGN: A 2-arm randomized controlled trial was conducted between October 2004 and June 2006. PARTICIPANTS: Of 350 men and women (> or = 18 years) initiating HAART, 53.7% were female, and 97% were on 1 fixed-dose combination pill twice a day. INTERVENTION: Participants were randomly assigned to receive 6 weeks (Monday through Friday; 30 daily visits) of peer-delivered, modified directly observed therapy (mDOT) or standard care. Peers provided education about treatment and adherence and sought to identify and mitigate adherence barriers. OUTCOME: Participants' self-reported medication adherence was assessed 6 months and 12 months after starting HAART. Adherence was defined as the proportion of prescribed doses taken over the previous 7 days. Statistical analyses were performed using intention-to-treat (missing = failure).
RESULTS: Intervention participants, compared to those in standard care, showed significantly higher mean medication adherence at 6 months (92.7% vs. 84.9%, difference 7.8, 95% confidence interval [CI]: 0.0.02, 13.0) and 12 months (94.4% vs. 87.7%, difference 6.8, 95% CI: 0.9, 12.9). There were no between-arm differences in chart-abstracted CD4 counts.
CONCLUSIONS: A peer-delivered mDOT program may be an effective strategy to promote long-term adherence among persons initiating HAART in resource-poor settings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693890      PMCID: PMC4044044          DOI: 10.1097/QAI.0b013e318153f7ba

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  44 in total

1.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.

Authors:  J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

2.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

Authors:  D R Bangsberg; S Perry; E D Charlebois; R A Clark; M Roberston; A R Zolopa; A Moss
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

3.  A comparison study of multiple measures of adherence to HIV protease inhibitors.

Authors:  H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

4.  Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

Authors:  H Knobel; A Guelar; A Carmona; M Espona; A González; J L López-Colomés; P Saballs; J L Gimeno; A Díez
Journal:  AIDS Patient Care STDS       Date:  2001-04       Impact factor: 5.078

5.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

Review 6.  Attaining higher goals in HIV treatment: the central importance of adherence.

Authors:  G H Friedland; A Williams
Journal:  AIDS       Date:  1999-09       Impact factor: 4.177

7.  Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring.

Authors:  S A Safren; M W Otto; J L Worth; E Salomon; W Johnson; K Mayer; S Boswell
Journal:  Behav Res Ther       Date:  2001-10

8.  Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.

Authors:  A Tuldrà; C R Fumaz; M J Ferrer; R Bayés; A Arnó; M Balagué; A Bonjoch; A Jou; E Negredo; R Paredes; L Ruiz; J Romeu; G Sirera; C Tural; D Burger; B Clotet
Journal:  J Acquir Immune Defic Syndr       Date:  2000-11-01       Impact factor: 3.731

9.  Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients.

Authors:  Claes Cederfjäll; Ann Langius-Eklöf; Knut Lidman; Regina Wredling
Journal:  AIDS Patient Care STDS       Date:  2002-12       Impact factor: 5.078

10.  Impact of a patient education program on adherence to HIV medication: a randomized clinical trial.

Authors:  Cécile Goujard; Noëlle Bernard; Nathalie Sohier; Dominique Peyramond; Florian Lançon; Judith Chwalow; Benoit Arnould; Jean-François Delfraissy
Journal:  J Acquir Immune Defic Syndr       Date:  2003-10-01       Impact factor: 3.731

View more
  63 in total

1.  Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy.

Authors:  Jean B Nachega; Richard E Chaisson; Rene Goliath; Anne Efron; Mohammad A Chaudhary; Malathi Ram; Chelsea Morroni; Hennie Schoeman; Amy R Knowlton; Gary Maartens
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

Review 2.  Impact of community-based support services on antiretroviral treatment programme delivery and outcomes in resource-limited countries: a synthetic review.

Authors:  Edwin Wouters; Wim Van Damme; Dingie van Rensburg; Caroline Masquillier; Herman Meulemans
Journal:  BMC Health Serv Res       Date:  2012-07-09       Impact factor: 2.655

3.  Community-based DOT-HAART accompaniment in an urban resource-poor setting.

Authors:  Maribel Muñoz; Karen Finnegan; Jhon Zeladita; Adolfo Caldas; Eduardo Sanchez; Miriam Callacna; Christian Rojas; Jorge Arevalo; Jose Luis Sebastian; Cesar Bonilla; Jaime Bayona; Sonya Shin
Journal:  AIDS Behav       Date:  2009-04-16

Review 4.  Attrition and related trends in scientific rigor: a score card for ART adherence intervention research and recommendations for future directions.

Authors:  K Rivet Amico; Jennifer J Harman; Megan A O'Grady
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

Review 5.  Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research.

Authors:  Michael J Stirratt; Christopher M Gordon
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

6.  Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa.

Authors:  Krisda Chaiyachati; Lisa R Hirschhorn; Frank Tanser; Marie-Louise Newell; Till Bärnighausen
Journal:  AIDS Patient Care STDS       Date:  2011-01-26       Impact factor: 5.078

7.  Patient-level moderators of the efficacy of peer support and pager reminder interventions to promote antiretroviral adherence.

Authors:  Samantha S Yard; David Huh; Kevin M King; Jane M Simoni
Journal:  AIDS Behav       Date:  2011-11

Review 8.  Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence.

Authors:  Amy Medley; Pamela Bachanas; Michael Grillo; Nina Hasen; Ugochukwu Amanyeiwe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

Review 9.  Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects.

Authors:  Larry W Chang; David Serwadda; Thomas C Quinn; Maria J Wawer; Ronald H Gray; Steven J Reynolds
Journal:  Lancet Infect Dis       Date:  2013-01       Impact factor: 25.071

10.  Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors.

Authors:  Man Charurat; Modupe Oyegunle; Renata Benjamin; Abdulrazaq Habib; Emeka Eze; Prince Ele; Iquo Ibanga; Samuel Ajayi; Maria Eng; Prosanta Mondal; Usman Gebi; Emilia Iwu; Mary-Ann Etiebet; Alash'le Abimiku; Patrick Dakum; John Farley; William Blattner
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.